CN Patent
CN103212143B — 用于执行医药注射的注射设备
Assigned to Novo Nordisk AS · Expires 2016-02-17 · 10y expired
What this patent protects
<b>本发明涉及预填充注射设备,具有封装在壳体内的容器和剂量设定机构。该注射设备包括轴向可变连接,使得活塞杆装置的远端和活塞之间的距离被最小化至优选为0。</b>
USPTO Abstract
<b>本发明涉及预填充注射设备,具有封装在壳体内的容器和剂量设定机构。该注射设备包括轴向可变连接,使得活塞杆装置的远端和活塞之间的距离被最小化至优选为0。</b>
Drugs covered by this patent
- Farxiga (DAPAGLIFLOZIN) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.